In addition to their use in exploring the molecular mechanisms of tumor initiation and progression [9,10,12,13], Kras-mutant models have been valuable in the pre-clinical setting and have led to the identification of modifiers of treatment response [14,15] and therapeutic strategies to specifically target Kras- mutant cancers [16]. This evidence concerns the gene KRAS and neoplasm.